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Background: Adult critically ill patients often suffer from acute
circulatory failure and those with low cardiac output may be treated
with inotropic agents. The aim of this Scandinavian Society of
Anaesthesiology and Intensive Care Medicine guideline was to pre-
sent patient-important treatment recommendations on this topic.
Methods: This guideline was developed according to GRADE. We
assessed the following subpopulations of patients with shock: (1)
shock in general, (2) septic shock, (3) cardiogenic shock, (4) hypov-
olemic shock, (5) shock after cardiac surgery, and (6) other types of
shock, including vasodilatory shock. We assessed patient-important
outcome measures, including mortality and serious adverse reactions.
Results: For all patients, we suggest against the routine use of any
inotropic agent, including dobutamine, as compared to placebo/no treat-
ment (very low quality of evidence). For patients with shock in general,
and in those with septic and other types of shock, we suggest using
dobutamine rather than levosimendan or epinephrine (very low quality
of evidence). For patients with cardiogenic shock and in those with
shock after cardiac surgery, we suggest using dobutamine rather than
milrinone (very low quality of evidence). For the other clinical ques-
tions, we refrained from giving any recommendations or suggestions.
Conclusions: Wesuggest against the routineuse of any inotropic agent
in adult patients with shock. If used, we suggest using dobutamine
rather than other inotropic agents for the majority of patients, however,
the quality of evidence was very low, implying high uncertainty on the
balance between the benefits andharms of inotropic agents.
Editorial comment
Failure to generate sufficient cardiac output is a challenge in patients with acute circulatory fail-
ure. This guideline analyzes the available evidence for increasing inotropy, which is scarce. It con-
cludes that no agent should be used on a routine basis, while dobutamine emerges as the drug of
choice when applied with caution to specific patient groups.
Acta Anaesthesiologica Scandinavica 62 (2018) 420–450
ª 2018 The Authors. Acta Anaesthesiologica Scandinavica published by John Wiley & Sons Ltd on behalf of Acta Anaesthesiologica Scandinavica Foundation
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and
distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.420
REVIEW ARTICLE
An international journal of anaesthesiology, intensive 
care, pain, and critical emergency medicine
Acute circulatory failure or shock is a life-threa-
tening condition that needs prompt and ade-
quate treatment, as it may progress to organ
failure and death. Shock is a common condition
in critical care medicine, affecting about one
third of patients in the intensive care unit
(ICU).1
Resuscitation of patients in shock must be
early and appropriate to prevent or limit vital
organ injury. Initial support of the failing cir-
culation usually includes fluid resuscitation
in combination with the administration of a
vasopressor.1 In two recently published Scan-
dinavian Society of Anaesthesiology and
Intensive Care Medicine (SSAI) clinical prac-
tice guidelines, we have proposed recommen-
dations regarding choice of fluid2 and choice
of first-line vasopressor3 in the management
of adult patients with acute circulatory fail-
ure. In collaboration with the Canadian Criti-
cal Care Society, SSAI has also recently
issued recommendations for blood pressure
targets in adult critically ill patients with
hypotension.4
Subsets of patients with shock, including
patients with heart failure may, however,
not respond adequately to volume expansion
and vasopressors, and additional support,
including administration of inotropic agents
may be required to restore cardiac output
and organ perfusion. Inotropic agents com-
monly used include the synthetic cate-
cholamine dobutamine, the endogenous
catecholamine epinephrine, the phosphodi-
esterase III inhibitor milrinone, and the
calcium sensitizer levosimendan.5 Further-
more, dopamine possesses inotropic proper-
ties, and is sometimes used as an inotropic
agent.6
The Clinical Practice Committee of the SSAI
initiated this guideline on choice of inotropic
agent in adult patients with acute circulatory
failure. The aim was to summarize the available
evidence and provide recommendations accord-
ing to current standards for trustworthy guide-
lines.7–9
An electronic version of this guideline can be
accessed at www.ssai.info/guidelines/
Methods
Process
The Clinical Practice Committee of SSAI
appointed national members of the guideline
task force for Acute Circulatory Failure (the
authors of this study). This group identified four
key interventions needing guidelines, including
fluid resuscitation,2 vasopressor therapy,3 ino-
tropic therapy, and cardiovascular diagnostics
and monitoring. This is the group’s third guide-
line: choice of inotropic agent for adult patients
with acute circulatory failure.
We have prepared this guideline according to
the AGREE statement.10
Clinical question
‘Which inotropic agent should be used for
adult critically ill patients with acute circula-
tory failure?’
Population
The population of interest was adult patients (as
defined in the original trials) with acute circula-
tory failure/shock (as defined in the original tri-
als) receiving inotropes in a high-dependency
setting in hospital, including the emergency
department, ICU, operating room, and recovery
room. The following subpopulations were
assessed: patients with (1) shock in general
(any type of shock), (2) septic shock, (3) cardio-
genic shock, (4) hypovolemic shock, (5) shock
after cardiac surgery, and (6) other types of
shock, including vasodilatory shock.
Acute circulatory failure and shock are used
interchangeably throughout this guideline, and
were defined as inadequate/hypoperfusion of
tissue and organs.
Intervention(s)
We assessed any dose of the following ino-
tropes: (1) levosimendan, (2) milrinone, (3) epi-
nephrine, (4) dopamine, and (5) placebo/no
treatment.
We defined inotropic agents as drugs with
positive inotropic effect leading to increased
stroke volume and cardiac output.
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Comparator
The control inotropic agent was dobutamine
(any dose).
We expected dobutamine to be the most
widely studied drug, and thus chose dobu-
tamine as the comparator and the other ino-
tropes as experimental interventions.
Outcome(s)
The following patient-important outcome mea-
sures11 were assessed at the time of longest fol-
low-up:
Critical outcomes
1. Short-term mortality (0–90 days, including
in-ICU and in-hospital mortality)
2. Long-term mortality (more than 90 days)
3. Quality of life as defined in the included trials
Important outcomes
4. Ischemic events as defined in the included
trials
5. Use of renal replacement therapy
6. Acute kidney injury as defined in the
included trials
7. Dysrhythmias as defined in the included
trials
8. Hospital length-of-stay (LOS)
We excluded systematic reviews and trials
done in children, those assessing prophylactic
use of inotropes, those not reporting the prede-
fined patient-important outcome measures, and
those not comparing dobutamine vs. another
inotropic agent, including those comparing
combinations of inotropes or head-to-head
comparison of other inotropes than dobu-
tamine. Systematic reviews and trials allowing
the use of adjuvant vasopressors were not
excluded if the vasopressor used was identical
in both arms. Cross-over trials and trials in
which patients were systematically treated
with either the intervention or comparator drug
prior to or after randomization were also
excluded.
Search strategy
We systematically searched PubMed (January
1966 to 25 September 2017), Cochrane Library
(Issue 4, September 2017), and Epistemonikos
for systematic reviews of randomized clinical tri-
als (RCTs) and RCTs comparing dobutamine
with other inotropic agents on 25 September
2017. No language restriction was employed.
We used the following search strategies:
1. PubMed: (dobutamine OR inotrope* OR inodilat*)
AND (levosimendan OR milrinone OR epinephrine
OR dopamine OR placebo OR ‘control’ OR ‘no
treatment’) AND (shock OR cardiac OR ‘heart
failure’). Filters: ‘Randomized controlled trials’
‘Systematic reviews’; and ‘Meta-analyses’.
2. Cochrane Library: ‘shock’ using the
‘Cochrane Review’ filter.
3. Epistemonikos: same search as for PubMed
adapted and without filters.
Statistics and GRADE
Specific clinical questions were formulated
using the relevant patient population and/or
clinical problem (P), the intervention (I) under
scrutiny, the comparator (C), and the predefined
patient-important outcomes (O)12 – PICO ques-
tions (Table 1).
Mantel-Haenszel statistics and random effects
models were used to generate summary esti-
mates/meta-analyses (Review Manager Version
5.3, The Nordic Cochrane Centre, The Cochrane
Collaboration, Copenhagen, Denmark).
We used trial sequential analysis (TSA) to
assess the risk of random errors (spurious find-
ings) due to repetitive testing and sparse data13.
TSA was applied using an a priori 20% relative
risk reduction, an alfa of 5%, beta of 90%, and
a control event proportion according to the
results from the included trials. TSA-adjusted
95% confidence intervals (CIs) were estimated
(Appendix S1) and are reported in the summary
of finding tables (Appendix S2). If less than 5%
of the required information size had been
accrued, no TSA could be conducted.
We used the Grading of Recommendations
Assessment, Development and Evaluation
(GRADE) system for formulating clinical ques-
tions, assessing the quality of evidence, generat-
ing anticipated absolute effects, and for moving
from evidence to recommendations.9 In brief, we
downgraded the quality of evidence (our confi-
dence in the effect estimates) for an intervention
for identified risks of bias (including baseline
imbalance, lack of blinding, academic/financial
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conflicts of interest, or early termination of trials),
inconsistency (unexplained heterogeneity), indi-
rectness (including extrapolation from other
patient populations or use of surrogate out-
comes), imprecision (wide confidence interval
around the effect estimate), or publication bias.
Accordingly, the quality of evidence was rated
from ‘high’ to ‘very low’. We used GradePro v.
3.5 to prepare summary of finding tables with
anticipated relative and absolute effects for the
outcomes, together with our confidence in the
effect estimates (Appendix S2).
When moving from evidence to recommenda-
tions, four factors were considered and integrated:
benefits and harms, quality of evidence, values
and preferences (of patients or their proxies), and
cost considerations. GRADE classifies recommen-
dations as ‘strong’ when virtually all informed
patients would choose the recommendedmanage-
ment strategy. ‘Weak’ recommendations apply
when fully informed patients would choose dif-
ferent management strategies, and reflects a close
call between benefits and harms, uncertainty
regarding treatment effects, questionable cost
effectiveness, or variability in values and prefer-
ences.9,14 The author group agreed upon all the
recommendations in this guideline. Strong recom-
mendations were given the wording ‘we recom-
mend’, andweak recommendations ‘we suggest’.
We followed standards for trustworthy guide-
lines through use of the GRADE system,
management of intellectual and financial
conflicts of interest on a recommendation per
recommendation basis (Appendix S3), a peer
review process, and a plan for updating of rec-
ommendations. We did not include patient rep-
resentatives in the guideline process.
Results
The results and recommendations based on the
PICOs are presented below, in Table 2, and in
the summary of finding tables given in
Appendix S2.
A. Dobutamine vs. other inotropes in
patients with shock in general
1. We suggest that dobutamine is used as
inotropic agent for patients with shock in
general rather than levosimendan (weak
recommendation, very low quality of evi-
dence).
No systematic reviews or RCTs reporting our
predefined patient-important outcome measures
have compared the use of dobutamine with that
of levosimendan in patients with shock in gen-
eral (Fig. 1, Table S1A in Appendix S2). In refer-
ence to our recommendation for patients with
septic shock, we suggest using dobutamine
(extrapolation).
The quality of evidence was downgraded due
to risk of bias, indirectness, and imprecision.
Table 1 Clinical research questions and PICO questions used to assess evidence relevant to this guideline statement.
Clinical question
PICO Question
Population (P) Intervention (I) Comparator (C) Outcomes (O)
Should
dobutamine or
other inotropes
be used for adult
patients with
acute circulatory
failure?
Adult patients with acute
circulatory failure divided into
the following subgroups:
1. Shock in general
2. Septic shock
3. Cardiogenic shock
4. Hypovolemic shock
5. Shock after cardiac surgery
6. Other types of shock, includ-
ing vasodilatory shock
1. Levosimendan
2. Milrinone
3. Epinephrine
4. Dopamine
5. Placebo/no treatment
Dobutamine 1. Short-term mortality
2. Long-term mortality
3. Quality of life
4. Ischemic events
5. Renal replacement therapy
6. Acute kidney injury
7. Dysrhythmias
8. Length of hospital stay
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Table 2 Key recommendations and quality of evidence.
Recommendation
Strength of the
recommendation Benefits and harms
Quality of evidence
Reason(s) for
downgrading Comments
A) Use of inotropes in patients with shock in general
1. We suggest using
dobutamine rather
than levosimendan
Weak No difference in short-term
mortality. Potential
harm of levosimendan25
Very low due to
imprecision, risk
of bias, and
indirectness
No data available for this
population; data extrapolated
from patients with septic shock.
The defined daily dose price of
levosimendan is about 22 times
higher than dobutamine
2. Dobutamine vs.
milrinone
None – – No data available; no relevant
populations to extrapolate
data from.
The defined daily dose price
of milrinone is about 100 times
higher than dobutamine
3. We suggest using
dobutamine rather
than epinephrine
Weak No difference in short-term
mortality, ischemic
events, and dysrhythmias.
Excessive vasoconstriction
and tachycardia of
epinephrine may affect
cardiac output adversely6
Very low due to
imprecision, risk
of bias, and
indirectness
No data available for this
population; data extrapolated
from patients with septic shock
4. Dobutamine vs.
dopamine
None – – No data available; no relevant
populations to extrapolate
data from
5. We suggest against
the use of dobutamine
as compared to
placebo/no treatment
Weak Potential harm of
dobutamine19
Very low due to
serious risk of bias,
and indirectness
No data available for this
population; data extrapolated
from patients with septic
shock (observational study)
B) Use of inotropes in patients with septic shock
1. We suggest using
dobutamine rather
than levosimendan
Weak No difference in short-term
mortality. Potential
harm of levosimendan25
Very low due to
imprecision, risk
of bias, and
indirectness
The defined daily dose price of
levosimendan is about 22 times
higher than dobutamine
2. Dobutamine vs.
milrinone
None – – No data available; no relevant
populations to extrapolate
data from.
The defined daily dose price
of milrinone is about 100 times
higher than dobutamine
3. We suggest using
dobutamine rather
than epinephrine
Weak No difference in short-term
mortality, ischemic
events, and dysrhythmias.
Excessive vasoconstriction
and tachycardia of
Very low due to
imprecision, risk
of bias, and
indirectness
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Table 2 (Continued)
Recommendation
Strength of the
recommendation Benefits and harms
Quality of evidence
Reason(s) for
downgrading Comments
epinephrine may affect
cardiac output adversely6
4. Dobutamine vs.
dopamine
None – – No data available; no relevant
populations to extrapolate
data from
5. We suggest against
the use of dobutamine
as compared to
placebo/no treatment
Weak Potential harm of
dobutamine19
Very low due to
serious risk of
bias, and
indirectness
No data available; no relevant
RCT populations to extrapolate
data from. Observational study
suggests harm from dobutamine
C) Use of inotropes in patients with cardiogenic shock
1. Dobutamine vs.
levosimendan
None – – The defined daily dose price of
levosimendan is about 22 times
higher than dobutamine
2. We suggest using
dobutamine rather
than milrinone
Weak No difference in short-term
mortality. Unknown
balance between the
benefits and harms
of milrinone15
Very low due to
imprecision, risk of
bias, and
indirectness
The defined daily dose price of
milrinone is about 100 times
higher than dobutamine
3. Dobutamine vs.
epinephrine
None – – No data available; no relevant
populations to extrapolate
data from
4. Dobutamine vs.
dopamine
None – – No data available; no relevant
populations to extrapolate
data from
5. We suggest against
the use of dobutamine
as compared to
placebo/no treatment
Weak No difference in short-term
mortality or long-term
mortality in patients
treated with dobutamine.
Very low due to
imprecision, risk of
bias, and
indirectness
High risk of random errors, which
cautions interpretations of the
findings in the meta-analyses.
Observational study in patients
with septic shock suggests harm
from dobutamine (extrapolation).
D) Use of inotropes in patients with hypovolemic shock
1. Dobutamine vs.
levosimendan
None – – No data available; no relevant
populations to extrapolate data from.
The defined daily dose price
of levosimendan is about
22 times higher than dobutamine
2. Dobutamine vs.
milrinone
None – – No data available; no relevant
populations to extrapolate
data from.
The defined daily dose price of
milrinone is about 100 times
higher than dobutamine
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Table 2 (Continued)
Recommendation
Strength of the
recommendation Benefits and harms
Quality of evidence
Reason(s) for
downgrading Comments
3. Dobutamine vs.
epinephrine
None – – No data available; no relevant
populations to extrapolate
data from
4. Dobutamine vs.
dopamine
None – – No data available; no relevant
populations to extrapolate
data from
5. We suggest against
the use of dobutamine
as compared to
placebo/no treatment
Weak Potential harm of
dobutamine19
Very low due to
serious risk of bias,
and indirectness
No data available for this
population; data extrapolated
from patients with septic shock
(observational study)
E) Use of inotropes in patients with shock after cardiac surgery
1. Dobutamine vs.
levosimendan
None No reliable differences in
short-term mortality,
ischemic events, acute
kidney injury, use
of renal replacement
therapy, and dysrhythmia
(high risk of random
errors). Potential harm
of levosimendan25
– The defined daily dose price of
levosimendan is about 22 times
higher than dobutamine.
Unknown balance between the
benefits and harms of
dobutamine vs. levosimendan
2. We suggest using
dobutamine rather
than milrinone
Weak No difference in acute
kidney injury and
dysrhythmias. Unknown
balance between
the benefits and
harms of milrinone15
Very low due to
imprecision, risk
of bias, and
indirectness
The defined daily dose price of
milrinone is about 100 times
higher than dobutamine
3. Dobutamine vs.
epinephrine
None – – No data available; no relevant
populations to extrapolate
data from
4. Dobutamine vs. dopamine None – – No data available; no relevant
populations to extrapolate
data from
5. We suggest against the
use of dobutamine as
compared to placebo/no
treatment
Weak Potential harm of
dobutamine19
Very low due to
serious risk of bias,
and indirectness
No data available for this
population; data extrapolated
from patients with septic shock
(observational study)
F) Use of inotropes in patients with other types of shock, including vasodilatory shock
1. We suggest using
dobutamine rather
than levosimendan
Weak No difference in short-term
mortality. Potential
harm of levosimendan25
Very low due to
imprecision, risk
of bias, and
indirectness
No data available for this
population; data extrapolated
from patients with septic shock.
The defined daily dose price of
levosimendan is about 22 times
higher than dobutamine
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2. Dobutamine vs. milrinone for patients
with shock in general: no recommenda-
tion/suggestion.
No systematic reviews or RCTs reporting our
predefined patient-important outcome measures
have compared the use of dobutamine with that
of milrinone in patients with shock in general
(Fig. 1, Table S1B in Appendix S2). We refrain
from giving any recommendations or sugges-
tions on using dobutamine vs. milrinone for
patients with shock in general, due to the lack
of data and no relevant populations to extrapo-
late from. Importantly, we recommend that if
clinicians prefer to use milrinone rather than
dobutamine in this population, they do so in
the context of high-quality RCTs, given the lack
of data on the balance between the benefits and
harms of milrinone in patients with acute
circulatory failure in general.15 Of note, the
defined daily dose price of milrinone is about
100 times higher than that of dobutamine.16
3. We suggest that dobutamine is used as ino-
tropic agent for patients with shock in general
rather than epinephrine (weak recommenda-
tion, very low quality of evidence).
No systematic reviews or RCTs reporting our pre-
defined patient-important outcome measures have
compared the use of dobutamine with that of epi-
nephrine in patients with shock in general (Fig. 1,
Table S1C in Appendix S2). In reference to our rec-
ommendation for patients with septic shock, we
suggest using dobutamine (extrapolation).
The quality of evidence was downgraded due
to imprecision, risk of bias, and indirectness.
Table 2 (Continued)
Recommendation
Strength of the
recommendation Benefits and harms
Quality of evidence
Reason(s) for
downgrading Comments
2. Dobutamine vs.
milrinone
None – – No data available; no relevant
populations to extrapolate data
from.
The defined daily dose price
of milrinone is about 100 times
higher than dobutamine
3. We suggest using
dobutamine rather
than epinephrine
Weak No difference in short-term
mortality, ischemic
events, and dysrhythmias.
Excessive vasoconstriction
and tachycardia of
epinephrine may
affect cardiac output
adversely6
Very low due to
imprecision, risk
of bias, and
indirectness
No data available for this
population; data extrapolated
from patients with septic shock.
Epinephrine is the drug of
choice in anaphylactic shock
4. Dobutamine vs. dopamine None – – No data available; no relevant
populations to extrapolate
data from
5. We suggest against
the use of dobutamine
as compared to
placebo/no treatment
Weak Potential harm of
dobutamine19
Very low due to
serious risk of bias,
and indirectness
No data available for this
population; data extrapolated
from patients with septic
shock (observational study)
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4. Dobutamine vs. dopamine for patients
with shock in general: no recommenda-
tion/suggestion.
No systematic reviews or RCTs reporting our
predefined patient-important outcome measures
have compared the use of dobutamine with that of
dopamine in patients with shock in general
(Fig. 1, Table S1D in Appendix S2). We refrain
from giving any recommendations or suggestions
on using dobutamine or dopamine for patients
with shock in general, due to the lack of data and
no relevant populations to extrapolate from.
Importantly, we recommend that if clinicians pre-
fer to use dopamine rather than dobutamine in
this population, they do so in the context of high-
quality RCTs, given the harm associated with use
of dopamine in patients with septic shock.17,18
5. We suggest against routine use of dobu-
tamine as inotropic agent for patients
with shock in general, as compared to pla-
cebo/no treatment (weak recommenda-
tion, very low quality of evidence).
No systematic reviews or RCTs reporting our
predefined patient-important outcome measures
have compared the use of dobutamine with that
of placebo/no treatment in patients with shock
in general (Fig. 1, Table S1E in Appendix S2).
Importantly, potential harm of dobutamine has
been suggested in a propensity-matched obser-
vational study in patients with septic shock.19
In reference to our recommendation for patients
with septic shock, we suggest against routine
use of dobutamine (extrapolation).
The quality of evidence was downgraded due
to serious risk of bias and indirectness.
B. Dobutamine vs. other inotropes in
patients with septic shock
1. We suggest that dobutamine is used as ino-
tropic agent for patients with septic shock
rather than levosimendan (weak recom-
mendation, very low quality of evidence).
In an updated meta-analysis comprising five tri-
als,20–24 we found no statistically significant differ-
ence in short-term mortality in patients with septic
shock treated with dobutamine vs. levosimendan
(Fig. 2, Fig. S1A in Appendix S1; Table S2A in
Appendix S2). None of the other predefined
patient-important outcome measures have been
assessed. In the recently published LEOPARDS
trial, in which adult patients with sepsis were ran-
domized to levosimendan or placebo, levosimendan
was associated with a lower likelihood of successful
weaning from mechanical ventilation and a higher
rate of supraventricular tachyarrhythmia compared
to placebo.25 This should caution the use of levosi-
mendan in patients with sepsis, which is why we
suggest using dobutamine rather than levosimen-
dan in patients with septic shock. Of note, the
defined daily dose price of levosimendan is about
22 times higher than that of dobutamine.16
A Short-term mortality
No data.
B Long-term mortality
No data.
C Quality of life
No data.
D Ischemic events
No data.
E Renal replacement therapy
No data.
F Acute kidney injury
No data.
G Dysrhythmias
No data.
H Hospital length-of-stay
No data.
Fig. 1. Forest plot of (A) short-term mortality, (B) long-term mortality,
(C) quality of life, (D) ischemic events, (E) renal replacement therapy,
(F) acute kidney injury, (G) dysrhythmias, and (H) hospital length-of-
stay in randomized trials of dobutamine vs. other inotropes for
patients with shock in general.
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The quality of evidence was downgraded due
to risk of bias, indirectness, and imprecision.
2. Dobutamine vs.milrinone for patients with
septic shock: no recommendation/suggestion.
No systematic reviews or RCTs reporting our
predefined patient-important outcome measures
have compared the use of dobutamine with that of
milrinone in patients with septic shock (Fig. 2,
Table S2B in Appendix S2). We refrain from giv-
ing any recommendations or suggestions on using
dobutamine or milrinone for patients with septic
shock, due to the lack of data and no relevant pop-
ulations to extrapolate from. Importantly, we rec-
ommend that if clinicians prefer to use milrinone
rather than dobutamine in this population, they
A Short-term mortality 
B Long-term mortality
No data.
C Quality of life
No data.
Fig. 2. Forest plot of (A) short-term mortality, (B) long-term mortality, (C) quality of life, (D) ischemic events, (E) renal replacement therapy, (F) acute
kidney injury, (G) dysrhythmias, and (H) hospital length-of-stay in randomized trials of dobutamine vs. other inotropes for patients with septic shock.
[Colour figure can be viewed at wileyonlinelibrary.com]
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do so in the context of high-quality RCTs, given
the lack of data on the balance between benefits
and harms of milrinone in patients with acute cir-
culatory failure in general.15 Of note, the defined
daily dose price of milrinone is about 100 times
higher than that of dobutamine.16
3. We suggest that dobutamine is used as ino-
tropic agent for patients with septic shock
rather than epinephrine (weak recommen-
dation, very low quality of evidence).
A small RCT comprising 60 patients with sep-
tic shock found no difference in short-term
mortality, ischemic events, and dysrhythmias
between patients treated with dobutamine
vs. epinephrine (Fig. 2, Table S2C in
Appendix S2).26 None of our other predefined
patient-important outcome measures have been
assessed. As excessive vasoconstriction and
tachycardia may affect cardiac output adversely
in most patients where an inotropic agent is
deemed indicated,6 we suggest using dobu-
tamine rather than epinephrine in patients with
septic shock.
D Ischemic events 
E Renal replacement therapy
No data.
F Acute kidney injury
No data.
Fig. 2. Continued
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The quality of evidence was downgraded due
to imprecision, risk of bias and indirectness.
4. Dobutamine vs. dopamine for patients with
septic shock: no recommendation/suggestion.
No systematic reviews or RCTs reporting our
predefined patient-important outcome measures
have compared use of dobutamine with dopa-
mine in patients with septic shock (Fig. 2,
Table S2D in Appendix S2). We refrain from giv-
ing any recommendations or suggestions on
using dobutamine or dopamine for patients
with septic shock, due to the lack of data and
no relevant populations to extrapolate from.
Importantly, we recommend that if clinicians
prefer to use dopamine rather than dobutamine
in this population, they do so in the context of
high-quality RCTs, given the harm associated
with use of dopamine in patients with septic
shock.17,18
5. We suggest against routine use of dobu-
tamine as inotropic agent for patients
with septic shock, as compared to pla-
cebo/no treatment (weak recommenda-
tion, very low quality of evidence).
G Dysrhythmias 
H Hospital length-of-stay
No data.
Fig. 2. Continued
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No systematic reviews or RCTs reporting our
predefined patient-important outcome measures
have compared use of dobutamine with pla-
cebo/no treatment in patients with septic shock
(Fig. 2, Table S2E in Appendix S2).
Importantly, potential harm of dobutamine has
been suggested in a propensity-matched observa-
tional study in patients with septic shock.19 Conse-
quently, we suggest against routine use of
dobutamine as inotropic agent for patients with
septic shock, as compared to placebo/no treatment.
The quality of evidence was downgraded due
to serious risk of bias and indirectness.
C. Dobutamine vs. other inotropes in
patients with cardiogenic shock
1. Dobutamine vs. levosimendan for
patients with cardiogenic shock: no recom-
mendation/suggestion.
In an updated meta-analysis comprising six
trials, we found no statistically significant dif-
ference in short-term mortality,27–32 long-term
mortality,27,30,31,33–35 ischemic events,30,34 acute
kidney injury,31 dysrhythmias,30,36 or hospital
length-of-stay37 in patients with cardiogenic
shock treated with dobutamine vs. levosimen-
dan (Fig. 3, Fig. S2A, B, D, E in Appendix S1,
Table S3A in Appendix S2). None of our other
predefined patient-important outcome measures
have been assessed. In the recently published
LEOPARDS trial in which adult patients with
sepsis were randomized to levosimendan or
placebo, levosimendan was associated with a
lower likelihood of successful weaning from
mechanical ventilation and a higher risk of
supraventricular tachyarrhythmia compared to
placebo.25 Of note, the defined daily dose price
of levosimendan is about 22 times higher than
dobutamine.16 We recommend that if clinicians
prefer to use levosimendan rather than dobu-
tamine in this population, they do so in the
context of high-quality RCTs, given the lack of
data on the balance between the benefits and
harms of levosimendan in patients with acute
circulatory failure in general, the suggested
harm of levosimendan in patients with sepsis,25
and the higher price.
2. We suggest that dobutamine is used as
inotropic agent for patients with cardiogenic
shock rather than milrinone (weak recom-
mendation, very low quality of evidence).
A small RCT comprising 30 patients with cardio-
genic shock38 found no difference in short-term
mortality between patients treated with dobu-
tamine vs. milrinone (Fig. 3, Table S3B in
Appendix S2). None of our other predefined
patient-important outcome measures have been
assessed. As the balance between the benefits and
harms of milrinone in patients with acute circula-
tory failure in general has been sparsely evaluated,
we suggest using dobutamine rather than milri-
none.15 The defined daily dose price of milrinone is
about 100 times higher than that of dobutamine.16
The quality of evidence was downgraded due
to imprecision, risk of bias, and indirectness.
3. Dobutamine vs. epinephrine for patients
with cardiogenic shock: no recommenda-
tion/suggestion.
No systematic reviews or RCTs reporting our
predefined patient-important outcome measures
have compared use of dobutamine with that of
epinephrine in patients with cardiogenic shock
(Fig. 3, Table S3C in Appendix S2).26 We refrain
from giving any recommendations or suggestions
on using dobutamine or epinephrine for patients
with cardiogenic shock, due to the lack of data
and no relevant populations to extrapolate from.
Importantly, excessive vasoconstriction and tachy-
cardia increase oxygen consumption and may
affect cardiac output adversely in most patients
where an inotropic agent is deemed indicated.6
4. Dobutamine vs. dopamine for patients
with cardiogenic shock: no recommenda-
tion/suggestion.
No systematic reviews or RCTs reporting our
predefined patient-important outcome measures
have compared use of dobutamine with
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dopamine in patients with cardiogenic shock
(Fig. 3, Table S3D in Appendix S2). We refrain
from giving any recommendations or suggestions
on using dobutamine or dopamine for patients
with cardiogenic shock, due to the lack of data
and no relevant populations to extrapolate from.
Importantly, we strongly recommend that if clini-
cians prefer to use dopamine rather than dobu-
tamine in this population, they do so in the
context of high-quality RCTs, given the harm
associated with use of dopamine in patients with
septic shock17,18 and in a subgroup analysis of
patients with cardiogenic shock in the SOAP 2
trial.39
5. We suggest against routine use of dobu-
tamine as inotropic agent for patients
with cardiogenic shock, as compared to
placebo/no treatment (weak recommen-
dation, very low quality of evidence).
In an updated meta-analysis, we found no sta-
tistically significant difference in short-term
A Short-term mortality
Fig. 3. Forest plot of (A) short-term mortality, (B) long-term mortality, (C) quality of life, (D) ischemic events, (E) renal replacement therapy, (F)
acute kidney injury, (G) dysrhythmias, and (H) hospital length-of-stay in randomized trials of dobutamine vs. other inotropes for patients with
cardiogenic shock. [Colour figure can be viewed at wileyonlinelibrary.com]
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mortality (1 trial, 199 patients)27 or long-term
mortality (2 trials, 245 patients)27,35 in patients
with cardiogenic shock treated with dobu-
tamine vs. placebo/no treatment (Fig. 3,
Fig. S2C in Appendix S1, Table S3E in
Appendix S2). TSA highlighted high risk of
random errors due to repetitive testing and
small sample sizes (Fig. S2 in Appendix S1),
which cautions interpretations of the findings
in the conventional meta-analysis. None of our
other predefined patient-important outcome
measures have been assessed. Importantly, as
potential harm of dobutamine has been sug-
gested in patients with septic shock, we sug-
gest against the routine use of dobutamine as
inotropic agent for patients with cardiogenic
shock, as compared to placebo/no treatment
(extrapolation).
The quality of evidence was downgraded due
to imprecision, indirectness, and risk of bias.
B Long-term mortality
C Quality of life
No data.
Fig. 3. Continued
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D. Dobutamine vs. other inotropes in
patients with hypovolemic shock
1. Dobutamine vs. levosimendan for
patients with hypovolemic shock: no rec-
ommendation/suggestion.
No systematic reviews or RCTs reporting our
predefined patient-important outcome measures
have compared use of dobutamine with levosi-
mendan in patients with hypovolemic shock
(Fig. 4, Table S4A in Appendix S2). We refrain
from giving any recommendations or sugges-
tions on using dobutamine or levosimendan for
patients with hypovolemic shock, due to the
lack of data and no relevant populations to
extrapolate from. In the recently published
LEOPARDS trial in which adult patients with
sepsis were randomized to levosimendan or pla-
cebo, levosimendan was associated with a lower
likelihood of successful weaning from mechani-
cal ventilation and a higher risk of supraventric-
ular tachyarrhythmia compared to placebo.25
This cautions use of levosimendan in other
patient groups, including patients with hypov-
olemic shock. Of note, the defined daily dose
price of levosimendan is about 22 times higher
D Ischemic events
E Renal replacement therapy
No data.
Fig. 3. Continued
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than dobutamine.16 Importantly, adequate fluid
resuscitation – and not inodilation - should be a
priority in patients with hypovolemic shock.
2. Dobutamine vs. milrinone for patients
with hypovolemic shock: no recommenda-
tion/suggestion.
No systematic reviews or RCTs reporting our
predefined patient-important outcome measures
have compared use of dobutamine with milri-
none in patients with hypovolemic shock
(Fig. 4, Table S4B in Appendix S2). We refrain
from giving any recommendations or sugges-
tions on using dobutamine or milrinone for
patients with hypovolemic shock, due to the
lack of data and no relevant populations to
extrapolate from. We recommend that if clini-
cians prefer to use milrinone rather than dobu-
tamine in this population, they do so in the
context of high-quality RCTs, given the lack of
data on the balance between benefits and harms
of milrinone in patients with acute circulatory
failure in general.15 Of note, the defined daily
dose price of milrinone is about 100 times
higher than that of dobutamine.16 Importantly,
adequate fluid resuscitation – and not inodila-
tion - should be a priority in patients with
hypovolemic shock.
3. Dobutamine vs. epinephrine for patients
with hypovolemic shock: no recommenda-
tion/suggestion.
F Acute kidney injury
Fig. 3. Continued
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No systematic reviews or RCTs reporting
our predefined patient-important outcome
measures have compared use of dobutamine
with epinephrine in patients with hypovolemic
shock (Fig. 4, Table S4C in Appendix S2).26
We refrain from giving any recommendations or
suggestions on using dobutamine or epinephr-
ine for patients with hypovolemic shock, due to
the lack of data and no relevant populations to
extrapolate from. Importantly, excessive vaso-
constriction and tachycardia increase oxygen
consumption and may affect cardiac output
adversely in most patients where an inotropic
agent is deemed indicated.6 Importantly, ade-
quate fluid resuscitation should be a priority in
patients with hypovolemic shock.
4. Dobutamine vs. dopamine for patients
with hypovolemic shock: no recommenda-
tion/suggestion.
No systematic reviews or RCTs reporting our
predefined patient-important outcome measures
have compared use of dobutamine with dopamine
in patients with hypovolemic shock (Fig. 4,
Table S4D in Appendix S2). We refrain from giv-
ing any recommendations or suggestions on using
dobutamine or dopamine for patients with hypov-
olemic shock, due to the lack of data and no rele-
vant populations to extrapolate from. Importantly,
we strongly recommend that if clinicians prefer to
G Dysrhythmias
Fig. 3. Continued
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use dopamine rather than dobutamine in this pop-
ulation, they do so in the context of high-quality
RCTs, given the harm associated with use of dopa-
mine in patients with septic shock17,18 and in a
subgroup analysis of patients with cardiogenic
shock in the SOAP 2 trial.39 Importantly, adequate
fluid resuscitation should be a priority in patients
with hypovolemic shock.
5. We suggest against routine use of dobu-
tamine as inotropic agent for patients
with hypovolemic shock, as compared to
placebo/no treatment (weak recommen-
dation, very low quality of evidence).
No systematic reviews or RCTs reporting our
predefined patient-important outcome measures
have compared use of dobutamine with pla-
cebo/no treatment in patients with hypovolemic
shock (Fig. 4, Table S4E in Appendix S2).
Importantly, potential harm of dobutamine has
been suggested in a propensity-matched
observational study in patients with septic
shock.19 In reference to our recommendation for
patients with septic shock, we suggest against
routine use of dobutamine (extrapolation). Of
note, adequate fluid resuscitation should be a
priority in patients with hypovolemic shock.
The quality of evidence was downgraded due
to serious risk of bias and indirectness.
E. Dobutamine vs. other inotropes in
patients with shock after cardiac surgery
1. Dobutamine vs. levosimendan for
patients with shock after cardiac surgery:
no recommendation/suggestion.
In an updated meta-analysis comprising four
trials and 470 patients, reduced short-term
mortality,40–43 fewer ischemic events,43 reduced
risk of acute kidney injury and use of renal
replacement therapy,40–43 and reduced risk of
dysrhythmias40,43 were suggested in patients
H Hospital length-of-stay
Fig. 3. Continued
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with shock after cardiac surgery treated with
levosimendan, as compared to dobutamine
(Fig. 5, Fig. S3A–C in Appendix S1,
Table S5A in Appendix S2). However, TSA
highlighted high risk of random errors due to
repetitive testing and small sample sizes
(Fig. S3 in Appendix S1), which cautions
interpretations of the findings in the conven-
tional meta-analysis. None of our other prede-
fined patient-important outcome measures have
been assessed. In the recently published
LEVO-CTS, CHEETAH, and LICORN trials44–46
no difference in outcome between levosimen-
dan and placebo in patients undergoing
planned cardiac surgery was found. Of note,
levosimendan was studied as a second-line
inotropic agent in these trials, and other ino-
tropic drugs, such as dobutamine, were
permitted. Importantly, in the LEOPARDS trial
in which adult patients with sepsis where
randomized to levosimendan or placebo,
levosimendan was associated with a lower
likelihood of successful weaning from mechan-
ical ventilation and a higher risk of supraven-
tricular tachyarrhythmia, as compared to
placebo.25 Of note, the defined daily dose
price of levosimendan is about 22 times higher
than dobutamine.16 We refrain from giving
any recommendations or suggestions on using
dobutamine or levosimendan for patients with
shock after cardiac surgery, due to the
unknown balance between the benefits and
harms of these agents in this population.
2. We suggest that dobutamine is used as
inotropic agent for patients with shock
after cardiac surgery rather than milrinone
(weak recommendation, very low quality
of evidence).
A small RCT comprising 120 patients with
shock after cardiac surgery47 found no differ-
ence in acute kidney injury and dysrhythmias
between patients treated with dobutamine
vs. milrinone (Fig. 5, Table S5B in
Appendix S2). None of our other predefined
patient-important outcome measures have
been assessed. As the balance between the
benefits and harms of milrinone in patients
with acute circulatory failure in general has
been sparsely evaluated,15 we suggest using
dobutamine rather than milrinone. Further-
more, the defined daily dose price of milri-
none is about 100 times higher than that of
dobutamine.16
The quality of evidence was downgraded due
to imprecision, indirectness, and risk of bias.
3. Dobutamine vs. epinephrine for patients
with shock after cardiac surgery: no rec-
ommendation/suggestion.
No systematic reviews or RCTs reporting our
predefined patient-important outcome measures
have compared use of dobutamine with
A Short-term mortality
No data.
B Long-term mortality
No data.
C Quality of life
No data.
D Ischemic events
No data.
E Renal replacement therapy
No data.
F Acute kidney injury
No data.
G Dysrhythmias
No data.
H Hospital length-of-stay
No data.
Fig. 4. Forest plot of (A) short-term mortality, (B) long-term mortality,
(C) quality of life, (D) ischemic events, (E) renal replacement therapy,
(F) acute kidney injury, (G) dysrhythmias, and (H) hospital length-of-
stay in randomized trials of dobutamine vs. other inotropes for
patients with hypovolemic shock.
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epinephrine in patients with shock post–cardiac
surgery (Fig. 5, Table S5C in Appendix S2).26 We
refrain from giving any recommendations or sug-
gestions on using dobutamine or epinephrine for
patients with shock after cardiac surgery, due to
the lack of data and no relevant populations to
extrapolate from. Importantly, excessive vasocon-
striction and tachycardia increase oxygen
consumption and may affect cardiac output
adversely in most patients where an inotropic
agent is deemed indicated.6
4. Dobutamine vs. dopamine for patients
with shock after cardiac surgery: no rec-
ommendation/suggestion.
A Short-term mortality
B Long-term mortality
No data.
C Quality of life
No data.
Fig. 5. Forest plot of (A) short-term mortality, (B) long-term mortality, (C) quality of life, (D) ischemic events, (E) renal replacement therapy, (F)
acute kidney injury, (G) dysrhythmias, and (H) hospital length-of-stay in randomized trials of dobutamine vs. other inotropes for patients with
shock after cardiac surgery. [Colour figure can be viewed at wileyonlinelibrary.com]
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No systematic reviews or RCTs reporting our
predefined patient-important outcome measures
have compared use of dobutamine with dopa-
mine in patients with shock after cardiac sur-
gery (Fig. 5, Table S5D in Appendix S2). We
refrain from giving any recommendations or
suggestions on using dobutamine or dopamine
for patients with shock after cardiac surgery,
due to the lack of data and no relevant popula-
tions to extrapolate from. Importantly, we rec-
ommend that if clinicians prefer to use
dopamine rather than dobutamine in this popu-
lation, they do so in the context of high-quality
RCTs, given the harm associated with use of
dopamine in patients with septic shock17,18 and
in a subgroup analysis of patients with
cardiogenic shock in the SOAP 2 trial.39
5. We suggest against routine use of dobu-
tamine as inotropic agent for patients with
shock after cardiac surgery, as compared to
placebo/no treatment (weak recommen-
dation, very low quality of evidence).
No systematic reviews or RCTs reporting our
predefined patient-important outcome measures
have compared use of dobutamine with pla-
cebo/no treatment in patients with shock after
cardiac surgery (Fig. 5, Table S5E in
Appendix S2). Importantly, as potential harm of
dobutamine has been suggested in patients with
septic shock, we suggest against the routine use
of dobutamine as inotropic agent for patients
D Ischemic events
Fig. 5. Continued
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with shock after cardiac surgery, as compared to
placebo/no treatment (extrapolation).
The quality of evidence was downgraded due
to serious risk of bias and indirectness.
F. Dobutamine vs. other inotropes in
patients with other types of shock, including
vasodilatory shock
1. We suggest that dobutamine is used as ino-
tropic agent for patients with other types of
shock including vasodilatory shock rather
than levosimendan (weak recommenda-
tion, very low quality of evidence).
No systematic reviews or RCTs reporting
our predefined patient-important outcome mea-
sures have compared use of dobutamine with
levosimendan in patients with other types of
shock including vasodilatory shock (Fig. 6,
Table S6A in Appendix S2). In reference to our
recommendation for patients with septic shock,
we suggest using dobutamine (extrapolation).
The quality of evidence was downgraded due
to risk of bias, indirectness, and imprecision.
2. Dobutamine vs. milrinone for patients
with other types of shock including
vasodilatory shock: no recommenda-
tion/suggestion.
E Renal replacement therapy
Fig. 5. Continued
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No systematic reviews or RCTs reporting our
predefined patient-important outcome measures
have compared use of dobutamine with milrinone
in patients with other types of shock including
vasodilatory shock (Fig. 6, Table S6B in
Appendix S2). We refrain from giving any recom-
mendations or suggestions on using dobutamine
or milrinone for patients with other types of shock
including vasodilatory shock, due to the lack of
data and no relevant populations to extrapolate
from. Importantly, we recommend that if clini-
cians prefer to use milrinone rather than dobu-
tamine in this population, they do so in the
context of high-quality RCTs, given the lack of
data on the balance between benefits and harms of
milrinone in patients with acute circulatory failure
in general.15 Of note, the defined daily dose price
of milrinone is about 100 times higher than that of
dobutamine.16
3. We suggest that dobutamine is used as
inotropic agent for patients with other
types of shock including vasodilatory
shock rather than epinephrine (weak rec-
ommendation, very low quality of evi-
dence).
No systematic reviews or RCTs reporting our
predefined patient-important outcome measures
have compared use of dobutamine with epi-
nephrine in patients with other types of shock
F Acute kidney injury
Fig. 5. Continued
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including vasodilatory shock (Fig. 6, Table S6C
in Appendix S2). In reference to our recommen-
dation for patients with septic shock, we suggest
using dobutamine (extrapolation). Importantly, in
vasodilatory shock caused by anaphylaxis, epi-
nephrine is the preferred drug of choice.
The quality of evidence was downgraded due
to risk of bias, indirectness, and imprecision.
4. Dobutamine vs. dopamine for patients with
other types of shock including vasodilatory
shock: no recommendation/suggestion.
No systematic reviews or RCTs reporting our
predefined patient-important outcome measures
have compared use of dobutamine with dopa-
mine in patients with other types of shock
including vasodilatory shock (Fig. 6, Table S6D
in Appendix S2). We refrain from giving any
recommendations or suggestions on using dobu-
tamine or dopamine for patients with other types
of shock including vasodilatory shock, due to
the lack of data and no relevant populations to
extrapolate from. Importantly, we strongly rec-
ommend that if clinicians prefer to use dopamine
rather than dobutamine in this population, they
G Dysrhythmias
H Hospital length-of-stay
No data.
Fig. 5. Continued
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do so in the context of high-quality RCTs, given
the harm associated with use of dopamine in
patients with septic shock17,18 and in a subgroup
analysis of patients with cardiogenic shock in
the SOAP 2 trial.39
5. We suggest against routine use of dobu-
tamine as inotropic agent for patients
with other types of shock including
vasodilatory shock, as compared to pla-
cebo/no treatment (weak recommenda-
tion, very low quality of evidence).
No systematic reviews or RCTs reporting our
predefined patient-important outcome measures
have compared use of dobutamine with pla-
cebo in patients with other types of shock
including vasodilatory shock (Fig. 6,
Table S6E in Appendix S2). In reference to
our recommendation for patients with septic
shock, we suggest against routine use of dobu-
tamine (extrapolation).
The quality of evidence was downgraded due
to serious risk of bias and indirectness.
Discussion
We were able to use existing systematic reviews
and RCTs to answer some of the clinical ques-
tions concerning choice of inotropic agents in
patients with septic shock, cardiogenic shock,
and in those with shock after cardiac surgery.
However, for patients with shock in general,
and those with hypovolemic shock, and other
types of shock, the quantity and quality of evi-
dence was very limited.
The most widely studied comparison was
dobutamine vs. levosimendan, whereas dobu-
tamine vs. milrinone, dobutamine vs. epinephr-
ine, and dobutamine vs. placebo/no treatment
have been sparsely assessed. No trials have
compared dobutamine vs. dopamine in any of
the six predefined subpopulations.
We propose no strong recommendations, as
the quantity and quality of evidence was very
low with large uncertainty about the direction
and magnitude of effect.
For all the six predefined subpopulations, we
suggest against the routine use of dobutamine,
as compared to placebo/no treatment (very low
quality of evidence). There are no data support-
ing that inotropic agents offer benefit as com-
pared to placebo or no treatment, and in
patients with septic shock, dobutamine has been
associated with adverse outcome.
For patients with shock in general and those
with septic shock and other types of shock, we
suggest using dobutamine over levosimendan
(very low quality of evidence). This was based
on an overall low confidence of benefit from
levosimendan, and importantly, potential harm,
as suggested in the LEOPARDS trial, in which
adult patients with sepsis randomized to treat-
ment with levosimendan had lower likelihood
of successful weaning from mechanical ventila-
tion and a higher rate of supraventricular tach-
yarrhythmia, as compared to placebo.25
For patients with shock in general and in
those with septic and other types of shock, we
suggest using dobutamine over epinephrine, as
A Short-term mortality
No data.
B Long-term mortality
No data.
C Quality of life
No data.
D Ischemic events
No data.
E Renal replacement therapy
No data.
F Acute kidney injury
No data.
G Dysrhythmias
No data.
H Hospital length-of-stay
No data.
Fig. 6. Forest plot of (A) short-term mortality, (B) long-term mortality,
(C) quality of life, (D) ischemic events, (E) renal replacement therapy,
(F) acute kidney injury, (G) dysrhythmias, and (H) hospital length-of-
stay in randomized trials of dobutamine vs. other inotropes for
patients with other types of shock, including vasodilatory.
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excessive vasoconstriction and tachycardia may
affect oxygen consumption and cardiac output
adversely in most patients where an inotropic
agent is deemed indicated (very low quality of
evidence).
For patients with cardiogenic shock and those
with shock after cardiac surgery, we suggest
using dobutamine over milrinone (very low
quality of evidence). This was based on overall
low confidence of benefit and insufficient
knowledge on harms from milrinone,15 and a
considerably higher defined daily dose price of
milrinone.
Because of no available data, no reliable data
on the balance between the benefits and harms,
or no relevant patient groups to extrapolate
from, we were not able to provide recommenda-
tions/suggestions for (1) dobutamine vs. milri-
none/dopamine in patients with shock in
general, and for those with septic and other
types of shock, (2) dobutamine vs. levosimen-
dan/epinephrine/dopamine for patients with
cardiogenic shock and those with shock after
cardiac surgery, and for (3) dobutamine vs.
levosimendan/milrinone/epinephrine/dopamine
in patients with hypovolemic shock.
As witnessed by the very low quality of evi-
dence supporting the suggestions of this guide-
line, there is large uncertainty on the balance
between the benefits and harms when using
inotropic agents in adult patients with acute cir-
culatory failure.48 Several interventions, which
are common practice in the ICU, have been
adopted based on the perception of improved
physiological parameters and physiological rea-
soning. This has the eminent risk of overestimat-
ing benefit and underestimating harm.49 In a
recently published systematic review, eight criti-
cal care interventions used in clinical practice
were shown to increase mortality.50 Furthermore,
there is empirical evidence within critical care
that research results based on data from trials
with lower quality have changed direction once
higher quality trials were published.51 Conse-
quently, we highly recommend that clinicians
who are using inotropic agents in patients with
acute circulatory failure, consider doing this in
the context of high-quality RCTs with low risk
of bias-assessing patient-important outcomes.
The strengths of this clinical practice guide-
line include the application of current standards
for trustworthy guidelines, including the
GRADE methodology which support a system-
atic and transparent process,9 and use of TSA to
assess the risk of random errors.13 The limita-
tions include the reliance upon existing system-
atic reviews for some recommendations, including
the risk of trial heterogeneity, indirectness, and
bias. Also, we did not include time to resolution
of shock or days free of inotropic support as out-
comes, as we did not expect that any trials had
assessed these otherwise patient-important out-
comes. Furthermore, not all of the included sys-
tematic reviews and trials have been designed as
a direct comparison between dobutamine and
another inotropic agent, as some trials have used
adjuvant vasopressors. Consequently, some of the
benefits and harms observed may partly be
caused by other adjuvant agents used and/or
induced changes in dosing of the inotropic agent
assessed. Our recommendations have been
restricted to those that can be based on findings
from RCTs exclusively, however, observational
studies may – although seldom and often biased -
provide evidence to help form some recommenda-
tions.52 Finally, our guideline group did not
include critical care nurses or other relevant stake-
holders such as patients, relatives, and representa-
tives of regulatory bodies and hospital owners.
Conclusion
For all adult patients with shock, we suggest
against the routine use of dobutamine as com-
pared to placebo/no treatment. If inotropic
agents are used, we suggest using dobutamine
rather than levosimendan or epinephrine in
patients with shock in general, and in those
with septic and other types of shock. In patients
with cardiogenic shock and in those with shock
after cardiac surgery, we suggest using dobu-
tamine rather than milrinone. For the remaining
clinical questions, we refrained from giving any
recommendations or suggestions. In general, the
quality of evidence was very low, implying high
uncertainty on the balance between the benefits
and harms when using inotropes in adult
patients with acute circulatory failure. Conse-
quently, RCTs with low risk of bias should be a
high research priority in settings where ino-
tropes are used.
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